CN110393293A - 一种冠心病专用型临床营养配方及其制备方法 - Google Patents
一种冠心病专用型临床营养配方及其制备方法 Download PDFInfo
- Publication number
- CN110393293A CN110393293A CN201910606017.4A CN201910606017A CN110393293A CN 110393293 A CN110393293 A CN 110393293A CN 201910606017 A CN201910606017 A CN 201910606017A CN 110393293 A CN110393293 A CN 110393293A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- powder
- heart disease
- coronary heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 56
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 38
- 230000035764 nutrition Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title abstract description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 31
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 239000011669 selenium Substances 0.000 claims abstract description 19
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011651 chromium Substances 0.000 claims abstract description 18
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 18
- 229930003935 flavonoid Natural products 0.000 claims abstract description 16
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 16
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 16
- 235000013311 vegetables Nutrition 0.000 claims abstract description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 15
- 239000011575 calcium Substances 0.000 claims abstract description 15
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 15
- 235000018102 proteins Nutrition 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 15
- 239000011718 vitamin C Substances 0.000 claims abstract description 15
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940046009 vitamin E Drugs 0.000 claims abstract description 14
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 14
- 239000011709 vitamin E Substances 0.000 claims abstract description 14
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 12
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011777 magnesium Substances 0.000 claims abstract description 12
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 12
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 12
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 12
- 239000011701 zinc Substances 0.000 claims abstract description 12
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 12
- 235000016804 zinc Nutrition 0.000 claims abstract description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 11
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 11
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 11
- 235000011649 selenium Nutrition 0.000 claims abstract description 11
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 11
- 239000011710 vitamin D Substances 0.000 claims abstract description 11
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 11
- 229940046008 vitamin d Drugs 0.000 claims abstract description 11
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 10
- 235000012721 chromium Nutrition 0.000 claims abstract description 10
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 10
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 10
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 10
- 239000011574 phosphorus Substances 0.000 claims abstract description 10
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 10
- 239000011734 sodium Substances 0.000 claims abstract description 10
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 9
- 229960000304 folic acid Drugs 0.000 claims abstract description 9
- 235000019152 folic acid Nutrition 0.000 claims abstract description 9
- 239000011724 folic acid Substances 0.000 claims abstract description 9
- 229910052742 iron Inorganic materials 0.000 claims abstract description 9
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 9
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 9
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 9
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 9
- 239000011719 vitamin A Substances 0.000 claims abstract description 9
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 9
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 9
- 229940045997 vitamin a Drugs 0.000 claims abstract description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 70
- 239000003094 microcapsule Substances 0.000 claims description 24
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 14
- 230000036961 partial effect Effects 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- 235000019197 fats Nutrition 0.000 claims description 11
- 235000005911 diet Nutrition 0.000 claims description 10
- 230000037213 diet Effects 0.000 claims description 10
- 229940091258 selenium supplement Drugs 0.000 claims description 10
- 241000234282 Allium Species 0.000 claims description 9
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims description 9
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 9
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 9
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 9
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 9
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 9
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 9
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 9
- 240000000171 Crataegus monogyna Species 0.000 claims description 9
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 9
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 9
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 9
- 108010073771 Soybean Proteins Proteins 0.000 claims description 9
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 9
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 9
- 235000021014 blueberries Nutrition 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 235000019710 soybean protein Nutrition 0.000 claims description 9
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 8
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 8
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 8
- 244000046146 Pueraria lobata Species 0.000 claims description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 8
- 244000269722 Thea sinensis Species 0.000 claims description 8
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 8
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 229940106134 krill oil Drugs 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229940029982 garlic powder Drugs 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 4
- 240000002234 Allium sativum Species 0.000 claims description 3
- 241001474374 Blennius Species 0.000 claims description 3
- 235000011201 Ginkgo Nutrition 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- -1 fatty acid Olefin Chemical class 0.000 claims description 3
- 235000004611 garlic Nutrition 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- 235000021388 linseed oil Nutrition 0.000 claims description 3
- 239000000944 linseed oil Substances 0.000 claims description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 2
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 102000008114 Selenoproteins Human genes 0.000 claims description 2
- 108010074686 Selenoproteins Proteins 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 241000219793 Trifolium Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 235000009973 maize Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000011781 sodium selenite Substances 0.000 claims description 2
- 235000015921 sodium selenite Nutrition 0.000 claims description 2
- 229960001471 sodium selenite Drugs 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract description 3
- 230000001228 trophic effect Effects 0.000 abstract description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 76
- 235000012000 cholesterol Nutrition 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 229960005069 calcium Drugs 0.000 description 12
- 201000001320 Atherosclerosis Diseases 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 10
- 229940091250 magnesium supplement Drugs 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000034994 death Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 150000003626 triacylglycerols Chemical group 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical compound O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 description 1
- IELOKBJPULMYRW-IKTKBOKFSA-N 4-oxo-4-[[(2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OC(CCC(O)=O)=O IELOKBJPULMYRW-IKTKBOKFSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BNBQLHFMDIMQCX-UHFFFAOYSA-N Cc1ncc(COP(O)(O)=O)c(C=O)c1O.Cc1ncc(COP(O)(O)=O)c(C=O)c1O Chemical compound Cc1ncc(COP(O)(O)=O)c(C=O)c1O.Cc1ncc(COP(O)(O)=O)c(C=O)c1O BNBQLHFMDIMQCX-UHFFFAOYSA-N 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 244000184861 Juglans nigra Species 0.000 description 1
- 235000013740 Juglans nigra Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 244000077233 Vaccinium uliginosum Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- DGUIQJBLMCNAIE-UHFFFAOYSA-N butanedioic acid;calcium Chemical compound [Ca].OC(=O)CCC(O)=O DGUIQJBLMCNAIE-UHFFFAOYSA-N 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229940087373 calcium oxide Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种冠心病专用型临床营养配方及其制备方法,该营养配方包括:麦芽糊精、异麦芽酮糖、蛋白质、脂肪、磷脂、膳食纤维、黄酮类植物、深色或绿色蔬菜、钠、磷、镁、钙、铁、锌、铬、硒、维生素A、维生素D、维生素E、维生素B1、维生素B2、维生素B6、维生素B12、维生素C、烟酸、叶酸、泛酸。上述营养配方基于冠心病患者的营养摄入,选用合理的基础营养素,可作为冠心病患者的日常营养均衡制剂,以实现营养均衡,改善冠心病患者营养结构,预防动脉粥样硬化,改善其机体健康状况。
Description
技术领域
本发明涉及特殊医学用途配方食品领域,具体涉及一种冠心病专用型临床营养配方及其制备方法。
背景技术
冠状动脉粥样硬化性心脏病,是指冠状动脉粥样硬化使血管腔狭窄或阻塞,和/或因冠状动脉功能性改变(痉挛)导致心肌缺血缺氧或坏死而引起的心脏病,统称冠状动脉性心脏病,简称冠心病。
冠心病是一种与不健康的生活方式,包括不合理饮食、缺乏运动、生活压力、心理不平衡等因素,所产生的与血脂代谢异常、糖尿病、高血压、肥胖、肾脏病等多种危险因素相关的疾病。另外其发病还与高同型半胱氨酸血症、遗传、高龄、男性性别等因素相关。
近年来,冠状动脉粥样硬化性心脏病发病率升高,并且其发病的年龄在渐渐年轻化。冠心病其好发年龄主要是40岁以上,其中男性占多数,尤其从事脑力活动者居多,是工业发达国家常见的流行病,已成为欧美等西方发达国家居民的主要死因之一。在发达国家其患病死亡率位于前列。近年来,随着高血压、糖尿病等疾病的流行以及人口老龄化问题的日趋严重,国内冠心病发病率和死亡率也在逐年升高。冠心病已成为严重危害人类健康的慢性疾病之一,其给个人、家庭和社会均带来巨大的损失和沉重的负担,是全球近30%患者的死亡原因。在美国,每25秒即发生一起急性冠脉事件,并导致每分钟一例的死亡。
在我国,随着居民生活水平的提高,人均谷类的消费大幅度减少,肉、蛋、奶及其他消费数倍增加,同时伴随户外运动减少,使疾病模式逐渐随之发生改变,营养过剩或营养不均衡所致慢性疾病发病逐年增多,其中冠心病是发病率最高的疾病之一,已成为影响人群健康的主要原因之一。
除遗传因素等不可控因素外,应尽可能控制和改善生活习惯,减少可控性危险因素,以对抗或推迟冠状动脉阻塞的发生和减少心肌梗死的发生。目前对于冠心病患者的治疗,临床医生将关注重点常常局限在冠状动脉介入诊治方法、药物临床治疗指南等方面,却常常忽视对于患者日常膳食营养干预的指导。据调查,冠心病与营养不平衡有一定关系,加强营养管理是防治冠心病的重要措施。而有研究证实,膳食营养是对动脉粥样硬化的形成有一定的作用,膳食中的某些物质是动脉粥样硬化及冠心病的危险因素,并对其发生和发展有着重要的调节作用。但目前用于冠心病患者的营养配方产品市场上较为罕见。
发明内容
为了克服现有技术中的缺陷,本发明针对冠心病患者饮食结构不合理、营养不均匀等不良现状,主要是通过膳食调控,合理搭配碳水化合物、蛋白质、脂肪的供给能量比值,选择多种维生素、矿物质、黄酮类植物和深色或绿色蔬菜,来改善冠心病患者营养结构,辅助改善机体健康状况。
为实现上述目的,本发明采用如下技术方案:
本发明的第一个目的是提供一种冠心病专用型临床营养配方,其包括如下组分及其重量份数:麦芽糊精30-35份、异麦芽酮糖20-25份、蛋白质18-22份、脂肪3~10份、磷脂0.01-0.06份、膳食纤维4-10份、黄酮类植物4-12份、深色或绿色蔬菜3-9份、钠0.10-0.16份、磷0.1-0.3份、镁0.08-0.3份、钙0.2-0.5份、铁0.008-0.02份、锌0.005-0.01份、铬0.01-0.026份、硒0.008-0.02份、维生素A 0.0003-0.0008份、维生素D 0.000001-0.0000015份、维生素E 0.005-0.01份、维生素B1 0.0008-0.002份、维生素B2 0.0008-0.002份、维生素B60.0008-0.002份、维生素B12 0.000001-0.000004份、维生素C 0.07-0.3份、烟酸0.008-0.03份、叶酸0.0001-0.0003份、泛酸0.001-0.004份。
为了进一步优化上述临床营养配方,本发明所采取的技术措施还包括:
进一步地,所述蛋白质为植物蛋白,其选自大豆分离蛋白、大豆肽、小麦低聚肽中的至少一种;更优选为大豆分离蛋白。动物食物含较高胆固醇及饱和脂肪酸,可明显升高血胆固醇,供给动物蛋白越多,动脉粥样硬化形成所需的时间越短,且病变越严重。植物蛋白,尤其是大豆蛋白既含有丰富的氨基酸,还有较高植物固醇,有利于胆酸排出,减少胆固醇合成、降低血胆固醇和预防动脉粥样硬化作用。补充适量高生物价优质蛋白质,其对血浆胆固醇水平有显著地降低作用,全面均衡地补充人体所需的8种必须氨基酸。
进一步地,所述脂肪中多不饱和脂肪酸与饱和脂肪酸比值为1:1-2:1。更进一步地,所述多不饱和脂肪酸中n-3脂肪酸来源于橄榄油微囊粉、紫苏籽油微囊粉、二十二碳六烯酸油脂、花生四烯酸油脂、鱼油微囊粉、亚麻籽油微囊粉、中链甘油三酯粉、大豆油微囊粉、玉米胚芽油微囊粉、菜籽油微囊粉、茶油微囊粉、葵花籽油微囊粉、海藻油、鸡蛋黄油、磷虾油、沙棘果油、大麻籽油中的至少一种;更优选为紫苏籽油微囊粉、沙棘果油、磷虾油。冠心病患者与高血压患者有类似脂类代谢异常,常有甘油三酯、总胆固醇、低密度脂蛋白水平升高,共同作用于血管内皮功能导致动脉粥样硬化的发生。所以膳食中需减少膳食脂肪的总量及饱和脂肪酸和胆固醇摄入,因饱和脂肪酸和血压呈正相关,而增加多不饱和脂肪酸(例如n-3脂肪酸),可改善脂代谢,因此选择多不饱和脂肪酸与饱和脂肪酸比值为1:1-2:1。亚油酸是合成有重要生理活性物质的原料,促进中性或酸性胆固醇自粪排出,抑制肝内脂质及脂蛋白合成,能降低血浆中胆固醇、甘油三酯、低密度脂蛋白、极低密度脂蛋白,增加高密度脂蛋白,抑制凝血过程,防止动脉粥样硬化形成,从而减少心血管事件。含有较多亚油酸的食物来源包括红花油、玉米油、棉籽油、大豆油、芝麻油、黑核桃油中的一种或多种组成。
进一步地,所述膳食纤维来源于菊粉、聚葡萄糖、低聚半乳糖、低聚果糖、低聚木糖、低聚异麦芽糖、抗性糊精、大豆纤维中的至少一种。冠心病的发病机理与脂代谢异常及胆固醇升高有关,积极控制血脂,配合合理的脂类摄入对预防和治疗动脉粥样硬化的发生和发展十分重要。血浆中所含脂类统称为血脂,一般说来,血脂中的主要成分是甘油三酯和胆固醇,与动脉粥样硬化有关的胆固醇主要有高密度胆固醇和低密度胆固醇。饮食中胆固醇摄入增加,导致血胆固醇水平升高,伴有冠心病的危险性增加。据报道,高甘油三酯血症常伴有低密度胆固醇的形成及高密度胆固醇的降低。摄入过多的饱和脂肪酸、反式脂肪酸、肉类和一些植物油,会提高胆固醇和低密度胆固醇的水平。而膳食纤维,可以减少胆固醇的吸收、影响胆固醇的代谢、促进胆固醇的排泄,降低血浆中胆固醇水平和甘油三酯水平,因此本营养配方适当添加了膳食纤维。
进一步地,所述黄酮类植物包括茶叶、大豆、葛根、山楂、银杏、蓝莓中的至少一种;更优选为:茶叶粉、山楂粉、葛根粉、蓝莓粉。黄酮类植物可提供抗氧化剂。茶叶中含有茶多酚、茶色素有助于抗氧化,经常饮茶能降低血清胆固醇浓度,调整胆固醇与磷脂比值等,能够防治动脉硬化,增强心脏收缩,加快心率,改善心肌功能。山楂富含维生素C和胡萝卜素外,还有黄酮类物质,有显著扩张冠状动脉、降低血清胆固醇和降压作用。银杏果可以降低血清胆固醇。葛根总黄酮和葛根素能明显的扩张冠状动脉,能降低正常心肌和心肌梗死区的氧消耗,具有增强心肌对缺血耐受性的作用。蓝莓含有丰富的花青素,具有很好的抗氧化功效。
进一步地,所述深色或绿色蔬菜包括大蒜、洋葱、香菇、紫花、苜蓿、木耳、海带、香菇、紫菜中的至少一种;更优选为大蒜粉、洋葱粉、黑木耳粉。本营养配方适当增加深色或绿色蔬菜的比例。海藻类及黑木耳等富含甲硫氨酸、钾、镁、铜、碘,均有利于冠心病治疗。大蒜和洋葱含硫化合物和精油,可降低血低密度脂蛋白和提高高密度脂蛋白,具有防治动脉粥样硬化的有效成份。
进一步地,所述硒来源于亚硒酸钠、富硒食用菌粉、富硒酵母、硒蛋白中的至少一种,所述铬来源于富铬酵母、富铬菌菇粉中至少一种;更优选地,所述硒来源于富硒酵母,所述铬来源于富铬酵母。硒具有较强的抗氧化作用,减少氧自由基对血管壁的损伤,能够抗动脉粥样硬化、降低全血粘度、血浆粘度,增加冠脉血流量,减少心肌的损伤程度,海味及海产品中含硒量较高。微量铬可提高高密度脂蛋白浓度,降低血清胆固醇含量,预防动脉粥样硬化的形成。
进一步地,所述冠心病专用型临床营养配方包括如下组分及其重量份数:麦芽糊精30-35份、异麦芽酮糖20-25份、大豆分离蛋白18-22份、紫苏籽油微囊粉2-5份、沙棘果油1-4份、磷虾油0.1-0.8份、磷脂0.01-0.06份、膳食纤维4-10份、茶叶粉1-3份、山楂粉1-3份、葛根粉1-3份、蓝莓粉1-3份、大蒜粉1-3份、洋葱粉1-3份、黑木耳粉1-3份、钠0.10-0.16份、磷0.1-0.3份、镁0.08-0.3份、钙0.2-0.5份、铁0.008-0.02份、锌0.005-0.01份、富铬酵母0.01-0.026份、富硒酵母0.008-0.02份、维生素A 0.0003-0.0008份、维生素D 0.000001-0.0000015份、维生素E 0.005-0.01份、维生素B1 0.0008-0.002份、维生素B2 0.0008-0.002份、维生素B6 0.0008-0.002份、维生素B12 0.000001-0.000004份、维生素C 0.07-0.3份、烟酸0.008-0.03份、叶酸0.0001-0.0003份、泛酸0.001-0.004份。
在上述营养配方中,添加了适量的磷脂。卵磷脂是血浆主要成分,在肝内合成,以结合蛋白的形式在血液中运输。卵磷脂使胆固醇酯化形成胆醇酯,酯化作用增强时,胆固醇不易在血管壁沉积,或使血管壁的胆固醇转入血浆而排出体外。黄豆卵磷脂能有效地降低血胆固醇浓度,并能防止动脉粥样硬化。
镁可以影响血脂代谢和血栓形成,促进纤维蛋白溶解,防止血小板凝聚。镁来源于硫酸镁、氯化镁、氧化镁、碳酸镁、磷酸氢镁、葡萄糖酸镁中的一种或多种。
锌过多或铜过低时血清胆固醇含量增加。锌铜比值高时,血清胆固醇也增高。而适当的锌铜比值可影响血清胆固醇的含量。锌来源于硫酸锌、葡萄糖酸锌、氧化锌、乳酸锌、柠檬酸锌中的一种或多种组合。
营养配方中的钙含量增加,因血钙可维持平滑肌细胞内外钙代谢的平衡,避免血管平滑肌的痉挛,从而有效预防血管硬化及降低血压。通过控制良好的血压,可使心力衰竭的发生率下降50%,冠心病的发生率下降15%,心肌梗死的发生率下降25%。钙可预防高血压及高脂膳食引起的高胆固醇血症。钙来源于碳酸钙、葡萄糖酸钙、柠檬酸钙、乳酸钙、L-乳酸钙、醋酸钙、氯化钙、磷酸三钙、氧化钙、硫酸钙中的一种或多种组合。
碘能转运血管壁上胆固醇等物质的沉积。
维生素C是一种天然的抗氧化物,具有中和、清除氧自由基的作用,使炎性细胞释放炎性因子能力下降,保护心肌细胞,并且维生素C参加机体的羟化反应,促进体内某些重要物质的合成和分解,降低毛细血管的通透性,增加血管韧性,减轻细胞水肿,改善微循环,加快受损心肌细胞的修复。大剂量维生素C可使胆固醇氧化为胆酸排出体外。蔬菜和水果含有丰富的维生素C、无机盐、纤维素和果胶。维生素C来源L-抗坏血酸、L-抗坏血酸钠、L-抗坏血酸钾、L-抗坏血酸-6-棕榈酸盐中的一种或多种组合。
维生素D的缺乏与动脉粥样硬化的严重程度呈正相关,甚至严重影响冠心病的发作,可能是由于参与炎症反应、抑制泡沫细胞的形成、抑制血管平滑肌细胞增殖、下调肾素-血管紧张素系统活性及改善胰岛素分泌及胰岛素抵抗相关。维生素D来源麦角钙化醇、胆钙化醇中的一种或多种组合。
维生素E能降低血中总胆固醇、低密度脂蛋白浓度,增加高密度脂蛋白的含量,有抗动脉粥样硬化的功效。动物实验关于维生素E抗动脉粥样硬化机制研究中,考虑维生素E可能通过影响低密度脂蛋白的氧化过程或胆固醇分解代谢酶的活性,从而可以抗动脉粥样硬化。维生素E还可以通过抑制平滑肌细胞增殖,从而延缓动脉管壁变窄;抑制血小板粘连、凝集和血小板释放反应;抑制粘附分子的表和功能,降低单核细胞与内皮间的反应,从而减少单核细胞向管中的迁移;减少白三稀的合成和强化前列环素的释放。这些均有利于减少冠心病的发生。维生素E来源d-α-生育酚、dl-α-生育酚、d-α-醋酸生育酚、dl-α-醋酸生育酚、混合生育酚浓缩物、维生素E琥珀酸钙、d-α-琥珀酸生育酚、dl-α-琥珀酸生育酚中的一种或多种组合。
维生素B1缺乏时使心肌代谢障碍,严重可导致心力衰竭,出现维生素B1缺乏性心脏病临床症状。维生素B1供给要充足,能量越多,糖类和蛋白质比例越高,则维生素B1需要量也越大。维生素B1来源于盐酸硫胺素、硝酸硫胺素中的一种或多种组合。
烟酸是一种强降脂脂溶性维生素,对治疗高脂蛋白血症有一定疗效。烟酸来源于烟酸、烟酸胺中的一种或多种组合。
维生素B6与亚油酸同时应用,能降低血脂。因维生素B6能促进亚油酸转变成花生四烯酸,花生四烯酸可使胆固醇氧化为胆酸。维生素B6来源于盐酸吡哆醇、5'-磷酸吡哆醛中的一种或多种组合。
本发明的第二个目的是提供一种上述冠心病专用型临床营养配方的制备方法方法,其包括如下步骤:称取预定量的各原料,将维生素、复合矿物质、膳食纤维、黄酮类植物、深色或绿色蔬菜混合,获得第一预混物,其粒径为50~200μm;将异麦芽酮糖、蛋白质、脂肪、磷脂混合,获得第二预混物,其粒径为50~200μm;将第二预混料和麦芽糊精先混合5~15分钟,然后将第一预混物加入混合10~30分钟,出料,分装。
进一步地,上述各原料均为粒径为50~200μm的粉末形式的原料,配置前及配置完成后均经过杀菌处理。
进一步地,所述营养配方的剂型包括营养粉、营养乳剂、胶囊剂、片剂、丸剂、口服液等。
与现有技术相比,本发明具有以下有益效果:
本发明所述的冠心病专用型临床营养配主要采用植物蛋白,其可减少胆固醇合成、降低血胆固醇和预防动脉粥样硬化;采用主要为n-3多不饱和脂肪酸,可改善脂代谢,降低血浆中胆固醇、甘油三酯等,抑制凝血过程,防止动脉粥样硬化形成;膳食纤维可减少胆固醇的吸收、影响胆固醇的代谢、促进胆固醇的排泄,降低血浆中胆固醇水平和甘油三酯水平;黄酮类植物和深色或绿色蔬菜能降低血清胆固醇浓度,扩张冠状动脉,具有防治动脉粥样硬化的功效。
本发明所述的营养配方通过膳食调控,合理搭配碳水化合物、蛋白质、脂肪的供给能量比值,选择多种维生素、矿物质、黄酮类植物和深色或绿色蔬菜,各种组分采用适宜的比例搭配,且其吸收快速、完全,可迅速补充冠心病患者所需营养,以改善冠心病患者营养结构,辅助改善机体健康状况。
具体实施方式
本发明提供一种冠心病专用型临床营养配方,其包括如下组分及其重量份数:包括如下组分及其重量份数:麦芽糊精30-35份、异麦芽酮糖20-25份、蛋白质18-22份、脂肪3~10份、磷脂0.01-0.06份、膳食纤维4-10份、黄酮类植物4-12份、深色或绿色蔬菜3-9份、钠0.10-0.16份、磷0.1-0.3份、镁0.08-0.3份、钙0.2-0.5份、铁0.008-0.02份、锌0.005-0.01份、铬0.01-0.026份、硒0.008-0.02份、维生素A 0.0003-0.0008份、维生素D 0.000001-0.0000015份、维生素E 0.005-0.01份、维生素B1 0.0008-0.002份、维生素B2 0.0008-0.002份、维生素B6 0.0008-0.002份、维生素B12 0.000001-0.000004份、维生素C 0.07-0.3份、烟酸0.008-0.03份、叶酸0.0001-0.0003份、泛酸0.001-0.004份。
下面结合实施例,对本发明的具体实施方式作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案,而不能以此来限制本发明的保护范围。
实施例1
本发明所述的冠心病专用型临床营养配方包括以下组分:
麦芽糊精35g、异麦芽酮糖25g、大豆分离蛋白18g、紫苏籽油微囊粉5g、沙棘果油4g、磷虾油0.8g、磷脂0.05g、膳食纤维6g、茶叶粉1g、山楂粉1g、葛根粉1g、蓝莓粉1g、大蒜粉1g、洋葱粉1g、黑木耳粉1g、钠0.1g、磷0.1g、镁0.2g、钙0.2g、铁0.015g、锌0.008g、富铬酵母0.02g、富硒酵母0.015g、维生素A 0.0003g、维生素D 0.0000015g、维生素E 0.01g、维生素B1 0.001g、维生素B2 0.001g、维生素B6 0.001g、维生素B12 0.000003g、维生素C 0.1g、烟酸0.02g、叶酸0.0002g、泛酸0.003g。
制备方法:按照组分表称量各组分,其中将维生素、复合矿物质、膳食纤维、黄酮类植物、深色或绿色蔬菜混合,获得第一预混物,其粒径为150μm;将异麦芽酮糖、蛋白质、脂肪、磷脂混合,获得第二预混物,其粒径为150μm;将第二预混料和粒径为150μm的麦芽糊精先混合10分钟,然后将第一预混物加入混合20分钟,出料,分装,根据本领域常用的辅料,制备成相应的剂型。
实施例2
本发明所述的冠心病专用型临床营养配方包括以下组分:
麦芽糊精30g、异麦芽酮糖20g、大豆分离蛋白18g、紫苏籽油微囊粉5g、沙棘果油4g、磷虾油0.8g、磷脂0.05g、膳食纤维6g、茶叶粉2g、山楂粉2g、葛根粉2g、蓝莓粉2g、大蒜粉2g、洋葱粉2g、黑木耳粉2g、钠0.1g、磷0.1g、镁0.2g、钙0.2g、铁0.015g、锌0.008g、富铬酵母0.02g、富硒酵母0.015g、维生素A 0.0003g、维生素D 0.0000015g、维生素E 0.01g、维生素B1 0.001g、维生素B2 0.001g、维生素B6 0.001g、维生素B12 0.000003g、维生素C 0.1g、烟酸0.02g、叶酸0.0002g、泛酸0.003g。
制备方法:按照组分表称量各组分,其中将维生素、复合矿物质、膳食纤维、黄酮类植物、深色或绿色蔬菜混合,获得第一预混物,其粒径为50μm;将异麦芽酮糖、蛋白质、脂肪、磷脂混合,获得第二预混物,其粒径为50μm;将第二预混料和粒径为50μm的麦芽糊精先混合15分钟,然后将第一预混物加入混合15分钟,出料,分装,根据本领域常用的辅料,制备成相应的剂型。
实施例3
本发明所述的冠心病专用型临床营养配方包括以下组分:
麦芽糊精35g、异麦芽酮糖20g、大豆分离蛋白18g、紫苏籽油微囊粉2g、沙棘果油1g、磷虾油0.1g、磷脂0.01g、膳食纤维6g、茶叶粉2g、山楂粉2g、葛根粉2g、蓝莓粉2g、大蒜粉2g、洋葱粉2g、黑木耳粉2g、钠0.1g、磷0.1g、镁0.2g、钙0.2g、铁0.015g、锌0.008g、富铬酵母0.01g、富硒酵母0.01g、维生素A 0.0003g、维生素D 0.0000015g、维生素E 0.01g、维生素B10.001g、维生素B2 0.001g、维生素B6 0.001g、维生素B12 0.000003g、维生素C 0.1g、烟酸0.02g、叶酸0.0002g、泛酸0.003g。
制备方法:按照组分表称量各组分,其中将维生素、复合矿物质、膳食纤维、黄酮类植物、深色或绿色蔬菜混合,获得第一预混物,其粒径为200μm;将异麦芽酮糖、蛋白质、脂肪、磷脂混合,获得第二预混物,其粒径为200μm;将第二预混料和粒径为200μm的麦芽糊精先混合5分钟,然后将第一预混物加入混合30分钟,出料,分装,根据本领域常用的辅料,制备成相应的剂型。
应用实施例
本实施例采用实施例1~3制备的营养粉进行治疗冠心病临床试验研究,其选取:诊断为冠心病的患者共200例,其中男性105例,女性95例,年龄在45~65岁,病程在0.5-4年。将患者随机分为实施例1组、实施例2组、实施例3组和对照组,每组50人。服用方法:实施例1组、实施例2组、实施例3组分别采用其制备的营养粉,每天两次,每次200mg,温水冲服,连续服用2个月;对照组按药品说明书服用硝苯地平。
疗效判定标准:
显效:临床症状及体征消失或基本消失,心电图恢复至正常或基本正常范围内;有效:心绞痛发作次数、程度及持续时间明显减轻,心电图ST段经治疗后回升超过0.05mV,T波由平坦变为直立;无效:心绞痛发作次数及静息心电图未见明显改善。
实验结果如下表所示:
实验组 | 实验例数 | 无效 | 有效 | 显效 |
对照组 | 50 | 12 | 14 | 24 |
实施例1组 | 50 | 5 | 15 | 30 |
实施例2组 | 50 | 7 | 14 | 29 |
实施例3组 | 50 | 8 | 15 | 27 |
由上可知,与对照组相比,本发明所述的营养配方对于冠心病的治疗效果优于硝苯地平,证明其能够有效预防和辅助冠心病的治疗。这说明本发明制备的营养配方,可作为冠心病患者的日常营养均衡制剂辅助治疗冠心病。
本发明通过选用合理的基础营养素,基于冠心病患者的营养摄入,对各组分的配比进行适应性调整,以实现营养均衡,改善冠心病患者营养结构,改善其机体健康状况。
以上对本发明的具体实施例进行了详细描述,但其只作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。
Claims (10)
1.一种冠心病专用型临床营养配方,其特征在于,包括如下组分及其重量份数:麦芽糊精30-35份、异麦芽酮糖20-25份、蛋白质18-22份、脂肪3~10份、磷脂0.01-0.06份、膳食纤维4-10份、黄酮类植物4-12份、深色或绿色蔬菜3-9份、钠0.10-0.16份、磷0.1-0.3份、镁0.08-0.3份、钙0.2-0.5份、铁0.008-0.02份、锌0.005-0.01份、铬0.01-0.026份、硒0.008-0.02份、维生素A 0.0003-0.0008份、维生素D 0.000001-0.0000015份、维生素E 0.005-0.01份、维生素B1 0.0008-0.002份、维生素B2 0.0008-0.002份、维生素B6 0.0008-0.002份、维生素B120.000001-0.000004份、维生素C 0.07-0.3份、烟酸0.008-0.03份、叶酸0.0001-0.0003份、泛酸0.001-0.004份。
2.根据权利要求1所述的一种冠心病专用型临床营养配方,其特征在于,所述蛋白质为植物蛋白,其选自大豆分离蛋白、大豆肽、小麦低聚肽中的至少一种。
3.根据权利要求1所述的一种冠心病专用型临床营养配方,其特征在于,所述脂肪中多不饱和脂肪酸与饱和脂肪酸比值为1:1-2:1。
4.根据权利要求3所述的一种冠心病专用型临床营养配方,其特征在于,所述多不饱和脂肪酸中n-3脂肪酸来源于橄榄油微囊粉、紫苏籽油微囊粉、二十二碳六烯酸油脂、花生四烯酸油脂、鱼油微囊粉、亚麻籽油微囊粉、中链甘油三酯粉、大豆油微囊粉、玉米胚芽油微囊粉、菜籽油微囊粉、茶油微囊粉、葵花籽油微囊粉、海藻油、鸡蛋黄油、磷虾油、沙棘果油、大麻籽油中的至少一种。
5.根据权利要求1所述的一种冠心病专用型临床营养配方,其特征在于,所述膳食纤维来源于菊粉、聚葡萄糖、低聚半乳糖、低聚果糖、低聚木糖、低聚异麦芽糖、抗性糊精、大豆纤维中的至少一种。
6.根据权利要求1所述的一种冠心病专用型临床营养配方,其特征在于,所述黄酮类植物包括茶叶、大豆、葛根、山楂、银杏、蓝莓中的至少一种。
7.根据权利要求1所述的一种冠心病专用型临床营养配方,其特征在于,所述深色或绿色蔬菜包括大蒜、洋葱、香菇、紫花、苜蓿、木耳、海带、香菇、紫菜中的至少一种。
8.根据权利要求1所述的一种冠心病专用型临床营养配方,其特征在于,所述硒来源于亚硒酸钠、富硒食用菌粉、富硒酵母、硒蛋白中的至少一种,所述铬来源于富铬酵母、富铬菌菇粉中至少一种。
9.根据权利要求1所述的冠心病专用型临床营养配方,其特征在于,包括如下组分及其重量份数:
麦芽糊精30-35份、异麦芽酮糖20-25份、大豆分离蛋白18-22份、紫苏籽油微囊粉2-5份、沙棘果油1-4份、磷虾油0.1-0.8份、磷脂0.01-0.06份、膳食纤维4-10份、茶叶粉1-3份、山楂粉1-3份、葛根粉1-3份、蓝莓粉1-3份、大蒜粉1-3份、洋葱粉1-3份、黑木耳粉1-3份、钠0.10-0.16份、磷0.1-0.3份、镁0.08-0.3份、钙0.2-0.5份、铁0.008-0.02份、锌0.005-0.01份、富铬酵母0.01-0.026份、富硒酵母0.008-0.02份、维生素A 0.0003-0.0008份、维生素D0.000001-0.0000015份、维生素E0.005-0.01份、维生素B1 0.0008-0.002份、维生素B20.0008-0.002份、维生素B6 0.0008-0.002份、维生素B12 0.000001-0.000004份、维生素C0.07-0.3份、烟酸0.008-0.03份、叶酸0.0001-0.0003份、泛酸0.001-0.004份。
10.一种如权利要求1~9中任一项所述的冠心病专用型临床营养配方的制备方法,其特征在于,包括如下步骤:称取预定量的各原料,将维生素、复合矿物质、膳食纤维、黄酮类植物、深色或绿色蔬菜混合,获得第一预混物,其粒径为50~200μm;将异麦芽酮糖、蛋白质、脂肪、磷脂混合,获得第二预混物,其粒径为50~200μm;将第二预混料和麦芽糊精先混合5~15分钟,然后将第一预混物加入混合10~30分钟,出料,分装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910606017.4A CN110393293A (zh) | 2019-07-05 | 2019-07-05 | 一种冠心病专用型临床营养配方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910606017.4A CN110393293A (zh) | 2019-07-05 | 2019-07-05 | 一种冠心病专用型临床营养配方及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110393293A true CN110393293A (zh) | 2019-11-01 |
Family
ID=68323947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910606017.4A Pending CN110393293A (zh) | 2019-07-05 | 2019-07-05 | 一种冠心病专用型临床营养配方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110393293A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114869995A (zh) * | 2022-03-24 | 2022-08-09 | 大医声科技(北京)有限公司 | 一种适用糖尿病患者多维营养素配方 |
CN114916665A (zh) * | 2022-04-08 | 2022-08-19 | 苏州麦轮生物科技有限公司 | 一种含有7,8-二羟基黄酮的营养补充剂及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103404875A (zh) * | 2013-08-29 | 2013-11-27 | 青岛海百合生物技术有限公司 | 一种供心血管疾病患者食用的复合海洋特膳食品 |
CN104855983A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 冠心病非全营养配方食品 |
CN108308597A (zh) * | 2017-12-05 | 2018-07-24 | 上海奥医生物医药科技有限公司 | 一种营养不良专用型临床营养配方及其制备方法 |
CN108669540A (zh) * | 2018-05-10 | 2018-10-19 | 上海奥医生物医药科技有限公司 | 脑卒中专用型临床营养配方及其制备方法 |
CN108703364A (zh) * | 2018-05-10 | 2018-10-26 | 上海奥医生物医药科技有限公司 | 脂肪酸代谢异常专用型临床营养配方及其制备方法 |
-
2019
- 2019-07-05 CN CN201910606017.4A patent/CN110393293A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103404875A (zh) * | 2013-08-29 | 2013-11-27 | 青岛海百合生物技术有限公司 | 一种供心血管疾病患者食用的复合海洋特膳食品 |
CN104855983A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 冠心病非全营养配方食品 |
CN108308597A (zh) * | 2017-12-05 | 2018-07-24 | 上海奥医生物医药科技有限公司 | 一种营养不良专用型临床营养配方及其制备方法 |
CN108669540A (zh) * | 2018-05-10 | 2018-10-19 | 上海奥医生物医药科技有限公司 | 脑卒中专用型临床营养配方及其制备方法 |
CN108703364A (zh) * | 2018-05-10 | 2018-10-26 | 上海奥医生物医药科技有限公司 | 脂肪酸代谢异常专用型临床营养配方及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114869995A (zh) * | 2022-03-24 | 2022-08-09 | 大医声科技(北京)有限公司 | 一种适用糖尿病患者多维营养素配方 |
CN114916665A (zh) * | 2022-04-08 | 2022-08-19 | 苏州麦轮生物科技有限公司 | 一种含有7,8-二羟基黄酮的营养补充剂及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2375079C2 (ru) | Поливитаминные и минеральные пищевые добавки | |
CA2715261C (en) | Food products containing omega-3 fatty acids | |
CN111084381A (zh) | 生酮营养代餐粉及应用 | |
CN1257408A (zh) | 有助于心血管健康的营养组合物 | |
WO2005023021A1 (ja) | ダイエット食品 | |
CN101715913B (zh) | 一种调节血脂的胶囊及其生产制作工艺 | |
CN105079009B (zh) | 预防和/或治疗心脑血管疾病的组合物 | |
CN103431392B (zh) | 一种供糖尿病患者食用的复合海洋特膳食品 | |
CZ26998A3 (cs) | Dvoufázový preparát | |
CN112137115A (zh) | 具有增强免疫力功效的生酮营养粉及其制备方法 | |
CN108703365A (zh) | 蛋白质过敏专用型临床营养配方及其制备方法 | |
CN110393293A (zh) | 一种冠心病专用型临床营养配方及其制备方法 | |
US20050013884A1 (en) | Compositions and methods for treating heart disease | |
CN103651949A (zh) | 一种养生减肥型调和油 | |
EP1371368A1 (en) | Salvianolic acid components as lipase inhibitors | |
KR102258546B1 (ko) | 유기농 케일을 주 성분으로 하는 건강기능식품 조성물 | |
CN103874425A (zh) | 转化膳食的方法 | |
Singh et al. | Food nutrition, science and technology | |
CN112189839A (zh) | 一种辅助降血脂组合物及其应用 | |
CN103404875B (zh) | 一种供心血管疾病患者食用的复合海洋特膳食品 | |
CN108851037A (zh) | 一种肾病综合征全营养食品的制备方法及其用途 | |
CN108260802A (zh) | 一种老年患者专用型临床营养配方及其制备方法 | |
CN101224005B (zh) | 一种具有全营养补充功效的营养片剂及其生产方法 | |
CN105831730A (zh) | 一种用于降三高的磷虾油复合特膳食品 | |
Suter | Health and nutrition: Opportunities for linseed in Australian food products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191101 |